Delcath Systems Announces $9.5 Million Private Placement
15 août 2019 18h02 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for...
Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester
29 juil. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...
Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging
22 juil. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Systems Closes $20 Million Private Placement
17 juil. 2019 16h05 HE
|
Delcath Systems, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCPK: DCTH) has closed on its previously announced private placement with gross...
Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019
16 avr. 2019 08h15 HE
|
Delcath Systems, Inc.
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
28 févr. 2019 10h38 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
08 févr. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
18 déc. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15 oct. 2018 10h57 HE
|
Delcath Systems, Inc.
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath...
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15 oct. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...